Novo Nordisk Annual Report 2021

Contents Introducing Novo Nordisk Strategic Aspirations Key risks Management Consolidated statements Additional information. سے Growing value market share in diabetes In the highly competitive diabetes market, we improved our value market share by 0.8 percentage points to 30.1%, reflecting strong demand for GLP-1 products across both North American and International Operations. There is a clear shift to greater use of GLP-1 therapies around the world and this segment's value share of the total diabetes market has increased to 26.5% compared with 21.9% 12 months ago. We continue to be the global market leader with our type 2 diabetes products Rybelsus, OzempicⓇ and VictozaⓇ, with a 52.7% share by value. OzempicⓇ, our once-weekly injectable semaglutide, is now available in 69 countries - including China - and RybelsusⓇ, our oral formulation of semaglutide, has been launched in 30 countries. Obesity sales Sales as reported Growth at CER DKK billion 10 8 6 4 64% 2 60% 42% 3% 55% Increasingly, healthcare providers are demanding diabetes treatments that not only control blood glucose levels but also have cardiovascular benefits. The fact that OzempicⓇ has been shown to significantly reduce the risk of major adverse cardiovascular events compared with placebo in people living with type 2 diabetes and ASCVD (atherosclerotic cardiovascular disease) is particularly important in this regard. Insulin sales in 2021 were mixed, with the growth driven by International Operations partially offset by lower sales in the US However, 2021 was a landmark year for digital health in our diabetes business, with the first launch of our smart insulin pens in Sweden and Germany followed by the UK launch in January 2022. By automatically recording insulin dosing information and viewing this alongside blood sugar information, the pens allow patients to better manage their disease with greater accuracy. This is a key part of our drive to provide more personalised treatment guidance to ensure patients using insulin maximise their time in the correct glycaemic range. 0 2017 2018 2019 2020 2021 Biopharm sales Sales as reported Growth at CER DKK billion 25 4% 4% 1% -16% 20 -1% 15 10 5 0 2017 2018 2019 2020 2021 Novo Nordisk Annual Report 2021 32 The smart pen initiative also paves the way for the digitalisation of the patient journey in other therapy areas in the future. The aim is simple: to use smart technology to help patients lead as normal a life as possible. Further growth in Biopharm In Biopharm, sales growth across International and North America Operations was driven by our treatments for rare blood disorders, including the newly launched products EsperoctⓇ and RefixiaⓇ, as well as Novo Eight® and NovoSevenⓇ. Sales of haemophilia A and haemophilia B products increased by 23% and 23% respectively. Overall demand for rare endocrine disorder products was flat, with an increase in international sales offset by a decline in North America. We remain the market leader in the global human growth disorder market with a value share of 36.3%, against 35.6% a year ago, reflecting the new indications that have been approved for our products and the global roll-out of our next-generation injection device. Strategic Aspirations 2025 Commercial execution - Strengthen Diabetes leadership - aim at global value market share of more than 1/3 - Strengthen Obesity leadership and double current sales (based on reported sales in 2019) - Secure a sustained growth outlook for Biopharm

View entire presentation